165 related articles for article (PubMed ID: 34732116)
1. The Therapeutic Potential of MAPK/ERK Inhibitors in the Treatment of Colorectal Cancer.
Pashirzad M; Khorasanian R; Fard MM; Arjmand MH; Langari H; Khazaei M; Soleimanpour S; Rezayi M; Ferns GA; Hassanian SM; Avan A
Curr Cancer Drug Targets; 2021; 21(11):932-943. PubMed ID: 34732116
[TBL] [Abstract][Full Text] [Related]
2. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
3. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
4. RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA.
Zhang M; Zhao S; Tan C; Gu Y; He X; Du X; Li D; Wei P
J Exp Clin Cancer Res; 2021 Jun; 40(1):200. PubMed ID: 34154626
[TBL] [Abstract][Full Text] [Related]
5. The Therapeutic Potential of MEK1/2 Inhibitors in the Treatment of Gynecological Cancers: Rational Strategies and Recent Progress.
Ghanaatgar-Kasbi S; Khazaei M; Rastgar-Moghadam A; Ferns GA; Hassanian SM; Avan A
Curr Cancer Drug Targets; 2020; 20(6):417-428. PubMed ID: 32329688
[TBL] [Abstract][Full Text] [Related]
6. MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
Chuang J; Wang C; Guo Y; Valenzuela V; Wu J; Fakih M
Clin Colorectal Cancer; 2021 Mar; 20(1):72-78. PubMed ID: 33436306
[TBL] [Abstract][Full Text] [Related]
7. Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death.
Jenkins LJ; Luk IY; Fairlie WD; Lee EF; Palmieri M; Schoffer KL; Tan T; Ng I; Vukelic N; Tran S; Tse JWT; Nightingale R; Alam Z; Chionh F; Iatropoulos G; Ernst M; Afshar-Sterle S; Desai J; Gibbs P; Sieber OM; Dhillon AS; Tebbutt NC; Mariadason JM
Mol Cancer Ther; 2023 Jan; 22(1):52-62. PubMed ID: 36343387
[TBL] [Abstract][Full Text] [Related]
8. CDKN2B antisense RNA 1 suppresses tumor growth in human colorectal cancer by targeting MAPK inactivator dual-specificity phosphatase 1.
Pan J; Lin M; Xu Z; Xu M; Zhang J; Weng Z; Lin B; Lin X
Carcinogenesis; 2021 Nov; 42(11):1399-1409. PubMed ID: 34436551
[TBL] [Abstract][Full Text] [Related]
9. MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy.
Zhang X; Ma L; Qi J; Shan H; Yu W; Gu Y
Mol Cell Biochem; 2015 Dec; 410(1-2):101-10. PubMed ID: 26318312
[TBL] [Abstract][Full Text] [Related]
10. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
11. Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition.
Yao W; Oh YT; Deng J; Yue P; Deng L; Huang H; Zhou W; Sun SY
J Biol Chem; 2016 Oct; 291(41):21694-21702. PubMed ID: 27576686
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
13. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
14. The potential role of regulatory microRNAs of RAS/MAPK signaling pathway in the pathogenesis of colorectal cancer.
Soleimani A; Rahmani F; Saeedi N; Ghaffarian R; Khazaei M; Ferns GA; Avan A; Hassanian SM
J Cell Biochem; 2019 Dec; 120(12):19245-19253. PubMed ID: 31512778
[TBL] [Abstract][Full Text] [Related]
15. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.
Ma Y; Wang L; Neitzel LR; Loganathan SN; Tang N; Qin L; Crispi EE; Guo Y; Knapp S; Beauchamp RD; Lee E; Wang J
Clin Cancer Res; 2017 Apr; 23(8):2027-2037. PubMed ID: 27678457
[No Abstract] [Full Text] [Related]
16. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
17. MAPK/ERK pathway inhibition is a promising treatment target for adrenocortical tumors.
Pereira SS; Monteiro MP; Costa MM; Ferreira J; Alves MG; Oliveira PF; Jarak I; Pignatelli D
J Cell Biochem; 2019 Jan; 120(1):894-906. PubMed ID: 30256438
[TBL] [Abstract][Full Text] [Related]
18. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
19. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.
Spreafico A; Tentler JJ; Pitts TM; Tan AC; Gregory MA; Arcaroli JJ; Klauck PJ; McManus MC; Hansen RJ; Kim J; Micel LN; Selby HM; Newton TP; McPhillips KL; Gustafson DL; Degregori JV; Messersmith WA; Winn RA; Eckhardt SG
Clin Cancer Res; 2013 Aug; 19(15):4149-62. PubMed ID: 23757356
[TBL] [Abstract][Full Text] [Related]
20. PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation.
Wang X; Wu F; Wang H; Duan X; Huang R; Tuersuntuoheti A; Su L; Yan S; Zhao Y; Lu Y; Li K; Yao J; Luo Z; Guo L; Liu J; Chen X; Lu Y; Hu H; Li X; Bao M; Bi X; Du B; Miao S; Cai J; Wang L; Zhou H; Ying J; Song W; Zhao H
J Exp Clin Cancer Res; 2020 Aug; 39(1):147. PubMed ID: 32746883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
